Does Medicare Cover Zepbound or Mounjaro?

It depends on why the drug is being prescribed, not on what it is.

Both Zepbound and Mounjaro are tirzepatide, made by Eli Lilly. Medicare treats them as different drugs because they carry different FDA-approved uses, and one of those uses, weight loss, has been off limits to Medicare drug plans since 2003.

As of September 2026 there are three separate doors. Most people qualify for exactly one.

Door	Covers	What you pay	Available
Part D, type 2 diabetes	Mounjaro	Plan copay, capped at $2,100/year	Now
Part D, obstructive sleep apnea	Zepbound	Plan copay, capped at $2,100/year	Now, if your plan lists it
Medicare GLP-1 Bridge	Zepbound KwikPen	$50 flat per month	July 1, 2026 to Dec 31, 2027

This is general information, not medical advice. Which drug and which dose is appropriate is a decision for you and a healthcare provider.

Why can’t Medicare just cover Zepbound for weight loss?

Because a federal statute says so. When Part D was created in 2003, Congress listed categories of drugs that plans may exclude, and agents used for weight loss are on that list. That exclusion is the reason a Part D plan can cover a $1,000-a-month drug for diabetes and refuse the identical molecule for obesity.

Everything below is a route around that exclusion, either by using a different approved indication or by paying for the drug outside the Part D benefit entirely.

Door one: Part D for Mounjaro and type 2 diabetes

This is the straightforward case. Mounjaro is approved for improving blood sugar in adults and children 10 and older with type 2 diabetes, and, since August 28, 2026, for reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk for them [12]. Type 2 diabetes is a covered indication, so Mounjaro is an ordinary Part D drug. The cardiovascular approval is new enough that its effect on Part D formulary placement will not be visible until the 2027 plan year at the earliest.

Most Part D and Medicare Advantage drug plans list it, generally at a preferred brand tier with prior authorization and quantity limits.

What shapes the bill:

• The 2026 Part D out-of-pocket cap is $2,100. Once your covered drug spending reaches it, the plan pays the full cost of covered drugs for the rest of the year. The maximum Part D deductible in 2026 is $615 [1].
• You cannot use the Mounjaro savings card. Lilly’s terms exclude every government beneficiary [2].
• The Medicare Prescription Payment Plan can even out the cash flow. It is a free federal tool that spreads covered Part D drug costs into fixed monthly payments across the plan year, and you can opt in at any time. Lilly’s own savings page points Medicare beneficiaries to it [2].

Practical tip: run your exact plan through the Medicare Plan Finder at medicare.gov during open enrollment, October 15 to December 7. Formularies reset every January 1, so a plan that covered Mounjaro last year may not this year.

Door two: Part D for Zepbound and obstructive sleep apnea

On December 20, 2024 the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity. It remains the first and only prescription medication approved specifically for OSA.

That approval matters for Medicare because OSA is not weight loss. A Part D plan may cover Zepbound for that indication. It is not required to [3][4].

In practice this means the answer is plan by plan. Some plans added Zepbound for OSA during the 2025 and 2026 formulary cycles; others did not. CMS does not publish a coverage rate, and the percentages circulating in secondary coverage are estimates rather than verified data.

If you want to pursue this route, the sequence is:

1. Get a documented diagnosis of moderate-to-severe obstructive sleep apnea. In practice that means a lab sleep study or a validated home sleep apnea test in your medical record. A clinician’s impression alone will not carry a prior authorization.
2. Confirm obesity is documented. Zepbound’s OSA indication is for adults with obesity.
3. Check the formulary before the prescription is written. Call your plan’s pharmacy benefits number and ask whether Zepbound appears on the formulary and what indication is covered. A prescription submitted under an obesity code will trigger the statutory exclusion automatically.
4. Expect prior authorization. Nearly every plan that covers Zepbound for OSA requires it, with the sleep study results attached.
5. If the plan does not list it, request a formulary exception with a letter of medical necessity, or compare plans during open enrollment.

There is one trap here that catches people. CMS rules say that if you have a condition that gives you a Part D pathway to a GLP-1, you must use that pathway. So having sleep apnea makes you ineligible for the GLP-1 Bridge [3][5]. You cannot pick whichever is cheaper.

Door three: the Medicare GLP-1 Bridge

The Bridge is a nationwide CMS demonstration that pays for certain GLP-1 drugs for weight management outside the normal Part D benefit. It started July 1, 2026 and, after CMS extended it, runs through December 31, 2027 [3][6].

What it covers: Foundayo tablets, Wegovy injection and Wegovy tablets, and the Zepbound KwikPen only. Medicare states explicitly that single-dose Zepbound vials and single-dose Zepbound pens are not covered [6]. Mounjaro is not covered.

What you pay: a flat $50 copayment (verified 2026-09-14) to the pharmacy for a one-month supply, 28 or 30 days depending on the drug, no matter your income [6]. This is a program copay for eligible Part D enrollees, not a cash price.

Who qualifies. You must meet all four:

1. You have Medicare Part D drug coverage, through a standalone drug plan, a Medicare Advantage plan with drug coverage, a Special Needs Plan, an employer or union group waiver plan, or the LI NET program. Private fee-for-service plans, cost contract plans and PACE organizations are excluded [3][6].
2. You are not already eligible to receive a GLP-1 through your Medicare drug plan. If your plan has been paying for a GLP-1 for any reason, you keep getting it that way. CMS defines GLP-1 drugs here as products containing semaglutide, tirzepatide, orforglipron, dulaglutide or liraglutide [6].
3. You do not have type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease [3][6].
4. You are at least 18 and at least one of these is true: BMI of 35 or higher; BMI of 30 or higher with certain types of heart failure, hard-to-control high blood pressure, or stage 3a or higher chronic kidney disease; or BMI of 27 or higher with prediabetes, or a prior heart attack or stroke, or blocked arteries in the legs or arms [6].

What the $50 does not do. Medicare is unusually blunt about this. The $50 does not count toward your yearly Part D deductible or out-of-pocket limit. It will not appear on your Part D Explanation of Benefits or on a Medicare Summary Notice. It cannot be lowered by Extra Help. And it cannot be spread across months using the Medicare Prescription Payment Plan [3][6].

CMS explains why in its own words: Bridge drugs are “provided outside of the Part D benefit payment flow and coverage,” so “the Part D deductible will not apply, no part of the $50 copay counts towards the beneficiary’s TrOOP costs, and there is no low-income subsidy (LIS) provided for LIS beneficiaries” [11]. TrOOP is the running total that decides when you reach the Part D out-of-pocket cap. In plain terms: a year of $50 Bridge copays leaves you exactly where you started on your other prescriptions. If you take several expensive drugs, that trade-off is worth working through with your plan or a free State Health Insurance Assistance Program counselor before you choose the Bridge over a Part D route.

One practical note: because Part D plans carry no financial risk for Bridge drugs and do not have to opt in, your plan cannot block you from using the Bridge [11]. You can check whether you qualify at Medicare.gov/glp1bridge or by calling 1-800-MEDICARE [11].

How the claim is routed. Because the Bridge sits outside Part D, the pharmacy uses special routing information. Lilly’s Medicare page publishes it: BIN 028918, PCN MEDDGLP1BR, Group Name GLP1Bridge, plus your Medicare Number (MBI) or the last four digits of your Social Security number [5]. LillyDirect Pharmacy can also fill Bridge prescriptions.

One good piece of fine print. Your prior authorization is valid through December 31, 2027, including through refills and dose increases, as long as you stay on the same GLP-1 [3][5]. You do not have to redo the paperwork every time you titrate up.

Ask for the right device. The Bridge covers the KwikPen, which holds all four weekly doses in one device and requires separate pen needles. If your prescription says single-dose pen or vial, it will not be covered [5][6].

What about the BALANCE Model?

BALANCE, short for Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth, is the longer-term CMS Innovation Center model the Bridge was meant to bridge to.

Under BALANCE, CMS negotiates prices and coverage terms directly with GLP-1 manufacturers on behalf of state Medicaid agencies and Part D plan sponsors. Eli Lilly and Novo Nordisk both agreed to participate, and the drug list is broader than the Bridge: all formulations of Foundayo, Mounjaro, Ozempic, Rybelsus and Wegovy, plus the KwikPen formulation of Zepbound [7]. The manufacturers agreed to a $245 net price per 30-day supply for Medicare in 2027; the Medicaid price is confidential to participating states [8].

Two things happened that people get wrong:

• The Medicare Part D piece did not launch for 2027. CMS set a participation threshold: plans covering at least 80% of the relevant Part D enrollment had to apply, measured against February 2026 enrollment, or CMS would not proceed in Medicare for 2027 [7]. Part D applications were due April 20, 2026; CMS announced on April 21, 2026 that the model would not launch in Medicare in 2027, and it has since been described as delayed to 2028 at the earliest [9]. CMS extended the Bridge through the end of 2027 instead [11]. BALANCE could still launch in Medicare in a later year.
• The Medicaid piece is live but quiet. States could join on a rolling basis from May 1, 2026, with applications due July 31, 2026 and start dates through January 1, 2027. As of mid-August 2026, the CMS model page had not named a single participating state [7].

Lilly’s own March 9, 2026 statement described the intended Part D design: from January 1, 2027, Zepbound, Mounjaro and orforglipron would be available through participating plans with most beneficiaries capped at $50 per month after the deductible, and cost sharing limited to $245 per month plus a dispensing fee before it [8]. That design is on hold for Medicare.

What if none of the doors fit?

If you are on Medicare, want tirzepatide for weight, and have sleep apnea or diabetes that pushes you out of the Bridge while your plan will not cover Zepbound, you are looking at paying outside your coverage.

Lilly’s self-pay prices are open to anyone with a valid on-label prescription regardless of insurance status: $299 a month for 2.5 mg, $399 for 5 mg and $449 for 7.5 mg through 15 mg, for the vial or the KwikPen. Zepbound’s own savings page explicitly shows this route for Medicare and other government beneficiaries.

Three warnings before you go that way:

• You must pay outside your Medicare coverage. You cannot submit the claim.
• Nothing you spend counts toward your Part D deductible or the $2,100 out-of-pocket cap. Medicare says the same about discount programs including TrumpRx.
• The $449 tier requires refilling within 45 days of the previous delivery. Miss it and Lilly’s regular self-pay prices apply, which its current pages put at $499 for 7.5 mg and $699 for the higher doses.

A note for military retirees

If you have TRICARE For Life, the picture changed on August 31, 2025. The Defense Health Agency stopped covering weight-loss medications including Zepbound for TFL beneficiaries and several other groups, and prior authorizations approved before that date became invalid [10]. TFL kept coverage of GLP-1s for type 2 diabetes, including Mounjaro.

The Defense Health Agency’s own Q&A notes that Medicare Part D may cover certain weight-loss medications for non-obesity conditions such as sleep apnea or cardiovascular risk, while TFL operates under separate federal rules that exclude weight-control medications regardless of comorbidities [10]. For some TFL beneficiaries, the Medicare GLP-1 Bridge is now the more useful door.

What to do next

1. Figure out which door you are in. Do you have type 2 diabetes? Door one. Documented moderate-to-severe OSA? Door two. Neither, and a qualifying BMI? Door three.
2. Call the pharmacy benefits number on your plan card and ask, by name, whether Zepbound or Mounjaro is on the formulary and for which indication.
3. Make sure the prescription names the right presentation. The Bridge covers only the KwikPen.
4. If you are denied, ask for the denial in writing and follow the appeal sequence: coverage determination, plan redetermination, then review by an independent review entity.
5. Re-check every fall. Formularies change January 1, the Bridge ends December 31, 2027, and BALANCE could still arrive in Part D in a later year.

Sources

1. GoodRx, Zepbound Medicare coverage and copay details: https://www.goodrx.com/zepbound/medicare-coverage
2. Eli Lilly, Mounjaro savings and coverage: https://mounjaro.lilly.com/savings-coverage
3. Medicare.gov, weight loss drugs: https://www.medicare.gov/coverage/weight-loss-drugs
4. Sleep Foundation, does Medicare cover Zepbound for sleep apnea: https://www.sleepfoundation.org/sleep-apnea/does-medicare-cover-zepbound-for-sleep-apnea
5. Eli Lilly, Zepbound Medicare Part D coverage: https://zepbound.lilly.com/medicare
6. CMS, Medicare GLP-1 Bridge: GLP-1 drugs for $50 a month: https://www.medicare.gov/publications/12234-medicare-glp-1-bridge-glp-1-drugs-for-50-a-month.pdf
7. CMS, BALANCE Model: https://www.cms.gov/priorities/innovation/innovation-models/balance
8. Eli Lilly statement on the CMMI BALANCE Model, March 9, 2026: https://investor.lilly.com/node/53986/pdf
9. Advisory Board, will CMS’s new BALANCE model make GLP-1s more affordable: https://www.advisory.com/daily-briefing/2026/04/15/balance-model-oi-ec
10. TRICARE, Q&A on TRICARE For Life coverage of weight loss medications: https://newsroom.tricare.mil/News/TRICARE-News/Article/4297241/qa-tricare-for-life-coverage-of-weight-loss-medications
11. CMS, Medicare GLP-1 Bridge FAQs: https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge
12. Eli Lilly, FDA approves Lilly’s Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes, August 28, 2026: https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-mounjaro-tirzepatide-reduce-cardiovascular
13. CMS, BALANCE Model Part D plans request for applications: https://www.cms.gov/priorities/innovation/files/balance-part-d-plans-rfa.pdf